



17th November 2016

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400001

Scrip Code: 500674

Dear Sirs,

Re: Sanofi India collaborates with National Institute of Pharmaceutical Education and Research (NIPER) Kolkata, to promote academic excellence and research

We enclose herewith copy of a Press Release being issued on the above subject, the contents of which are self-explanatory.

Thanking you,

Yours faithfully,
SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to read "GIRISH", with a horizontal line underneath it.

GIRISH TEKCHANDANI
COMPANY SECRETARY

Encl: a/a



**Sanofi India collaborates with
National Institute of Pharmaceutical Education and Research (NIPER)
Kolkata, to promote academic excellence and research**

New Delhi, India – 17th November '16 – Sanofi India Limited (SIL) signed a Memorandum of Understanding (MoU) with NIPER Kolkata, in the presence of H.E. President of India Pranab Mukherjee. The collaboration with NIPER Kolkata, an autonomous body set up under the aegis of Department of Pharmaceuticals, Government of India, will promote academic excellence and research in the areas of pharmaceuticals and consumer healthcare products, to cater to the current and future needs of the Pharmaceutical industry.

Through this initiative, Sanofi India will:

- Participate in revision or formulation of curriculum for a Post-Graduate (M.S./Ph.D. programme
- Provide opportunities of internship or project work to NIPER Kolkata M.S./Ph.D. students at manufacturing sites
- Ensure association of R&D heads with the dissertation work of NIPER Students
- Provide career growth opportunities
- Undertake collaborative research activities in identified areas

“The era of Academia-Industry collaboration to address the mammoth task of capacity building to meet our healthcare challenges has well and truly begun. Only a well-equipped and trained workforce can face future challenges and cater to the vast healthcare needs of the nation. We are proud to associate with NIPER Kolkata in this collaborative exercise to hone the students’ skill-sets, and empower them for future, based on our practical knowledge and research experience.” said Dr. Shailesh Ayyangar, Managing Director, Sanofi India Limited.

As per the MoU, the key deliverables for Sanofi India will be to assist NIPER Kolkata foster students with updated knowledge, and who are ready for the pharmaceutical industry. The collaboration will focus in the areas of NIPER Kolkata’s expertise:

- Repurposing of Existing Pharmaceuticals
- Novel Small Molecules for Anti-Diabetics and Drug Resistant Tuberculosis
- API by Synthetic Biology / Cell Factory
- Phyto-pharmaceuticals
- Rare Diseases of Public Health Importance

About NIPER

National Institute of Pharmaceutical Education and Research (NIPER), Kolkata was created in 2007 under the aegis of Ministry of Chemicals & Fertilizer as a centre of excellence for higher education, research and development in pharmaceutical sciences. The institute was declared as an Institute of National importance by Government of India through Act of Parliament (NIPER Act 1998 & NIPER amendment Act 2007).

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Aparna THOMAS

Tel. : +91 (0)22 28032169

aparna.thomas@sanofi.com

Nikita Merchant

Tel.: +91 (0)22 28032112

nikita.merchant@sanofi.com